Gemcitabine-induced Chronic Systemic Capillary Leak Syndrome

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2017 Sep 1

PMID 28855215

Citations 6

Authors

Ravneet Bajwa

Jason Starr

Karen Daily

Affiliations

Soon will be listed here.

Abstract

A 56-year-old woman presented with anasarca, hypoalbuminaemia and hypotension following cycle 3 day 1 of adjuvant gemcitabine for stage II pancreatic cancer. Due to the temporal nature of presentation, suspicion for gemcitabine-induced capillary leak syndrome was included in the differential diagnosis. Vascular endothelial growth factor levels were elevated at 707 pg/mL (reference range: 9-86 pg/mL). Corticosteroids were initiated, resulting in complete resolution of symptoms and hypotension. The patient suffered relapse of symptoms on discontinuation of steroids, further supporting chronic capillary leak syndrome.

Citing Articles

Systemic Capillary Leak Syndrome (SCLS) Presentation in Patients Receiving Anti-cancer Treatments.

Anipindi M, Kacarow J, Bitetto D Cureus. 2023; 15(4):e38335.

PMID: 37261188 PMC: 10228707. DOI: 10.7759/cureus.38335.

Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Lin C, Galal A, Rizzieri D, Chawla S, Lee S, Georgy A Cancer Invest. 2023; :1-10.

PMID: 36657101 PMC: 10387504. DOI: 10.1080/07357907.2022.2162073.

Anticancer Drug-Induced Capillary Leak Syndrome.

Izzedine H, Mathian A, Amoura Z, Ng J, Jhaveri K Kidney Int Rep. 2022; 7(5):945-953.

PMID: 35570987 PMC: 9091576. DOI: 10.1016/j.ekir.2022.02.014.

Systemic capillary leak syndrome following granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report.

Al Sharie A, Al Zubi Y, Al Sharie S, Baydoun H, Atawneh F, Alshari O Memo. 2022; 15(2):143-148.

PMID: 35096191 PMC: 8785001. DOI: 10.1007/s12254-021-00789-z.

Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome.

Keskin H, Cadirci K, Demirkazik A, Akbulut H, Yalcin B Biomark Cancer. 2019; 11:1179299X19854447.

PMID: 31217693 PMC: 6558530. DOI: 10.1177/1179299X19854447.

References

Lesterhuis W, Rennings A, Leenders W, Nooteboom A, Punt C, Sweep F . Vascular endothelial growth factor in systemic capillary leak syndrome. Am J Med. 2009; 122(6):e5-7. DOI: 10.1016/j.amjmed.2009.01.020. View

Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer J . Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004; 18(1):85-91. DOI: 10.1046/j.0767-3981.2003.00206.x. View

Kapoor P, Greipp P, Schaefer E, Mandrekar S, Kamal A, Gonzalez-Paz N . Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. Mayo Clin Proc. 2010; 85(10):905-12. PMC: 2947962. DOI: 10.4065/mcp.2010.0159. View

Prete M, Urso L, Fatone M, Pinto V, Perosa F . Antiphospholipids Syndrome Complicated by a Systemic Capillary Leak-Like Syndrome Treated With Steroids and Intravenous Immunoglobulins: A Case Report. Medicine (Baltimore). 2016; 95(5):e2648. PMC: 4748902. DOI: 10.1097/MD.0000000000002648. View

Vander Els N, Miller V . Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest. 1999; 114(6):1779-81. DOI: 10.1378/chest.114.6.1779. View

Baron D, Mayo A, Kluger Y . Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease. Clin Oncol (R Coll Radiol). 2006; 18(1):90-1. DOI: 10.1016/j.clon.2005.09.003. View

Pavlakis N, Bell D, Millward M, LEVI J . Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997; 80(2):286-91. DOI: 10.1002/(sici)1097-0142(19970715)80:2<286::aid-cncr17>3.0.co;2-q. View

Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B . Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol. 2002; 25(1):96-100. DOI: 10.1097/00000421-200202000-00021. View

Duron L, Delestre F, Amoura Z, Arnaud L . [Idiopathic and secondary capillary leak syndromes: A systematic review of the literature]. Rev Med Interne. 2015; 36(6):386-94. DOI: 10.1016/j.revmed.2014.11.005. View

10.

Druey K, Greipp P . Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010; 153(2):90-8. PMC: 3017349. DOI: 10.7326/0003-4819-153-2-201007200-00005. View

11.

Xie Z, Ghosh C, Patel R, Iwaki S, Gaskins D, Nelson C . Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood. 2012; 119(18):4321-32. PMC: 3359743. DOI: 10.1182/blood-2011-08-375816. View

12.

Plunkett W, Huang P, Searcy C, Gandhi V . Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996; 23(5 Suppl 10):3-15. View

13.

Biswas S, Nik S, Corrie P . Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol). 2005; 16(8):577-9. DOI: 10.1016/j.clon.2004.06.019. View

14.

Airaghi L, Montori D, Santambrogio L, Miadonna A, Tedeschi A . Chronic systemic capillary leak syndrome. Report of a case and review of the literature. J Intern Med. 2000; 247(6):731-5. DOI: 10.1046/j.1365-2796.2000.00693.x. View